BioLine RX Ltd (BLRX) — Working Capital to Net Assets Ratio
BioLine RX Ltd (BLRX) has a Working Capital to Net Assets ratio of 76.1% as of September 2025. Working capital of ILA14.86 Million (current assets of ILA28.52 Million minus current liabilities of ILA13.67 Million) is measured against net assets of ILA19.53 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See BLRX net asset quality score to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
BioLine RX Ltd Working Capital to Net Assets (2011–2024)
This chart shows how BioLine RX Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the ratio stands at 76.1%, reflecting working capital of ILA14.86 Million against net assets of ILA19.53 Million ILA. Check BLRX goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for BioLine RX Ltd (2011–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for BioLine RX Ltd from 2011 to 2024, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see how much is BioLine RX Ltd worth.
| Year | WC/NA Ratio | Working Capital (ILA) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 86.9% | ILA11.70 Million | ILA13.46 Million | ILA27.10 Million | ILA15.41 Million | ▲ +53.6 pp |
| 2023 | 33.3% | ILA4.40 Million | ILA13.22 Million | ILA47.18 Million | ILA42.78 Million | ▼ -48.0 pp |
| 2022 | 81.3% | ILA41.32 Million | ILA50.84 Million | ILA52.00 Million | ILA10.68 Million | ▲ +11.2 pp |
| 2021 | 70.0% | ILA47.69 Million | ILA68.09 Million | ILA57.40 Million | ILA9.72 Million | ▲ +14.5 pp |
| 2020 | 55.6% | ILA12.24 Million | ILA22.03 Million | ILA22.88 Million | ILA10.64 Million | ▲ +6.9 pp |
| 2019 | 48.7% | ILA16.24 Million | ILA33.38 Million | ILA28.21 Million | ILA11.97 Million | ▼ -12.4 pp |
| 2018 | 61.1% | ILA25.23 Million | ILA41.32 Million | ILA31.98 Million | ILA6.75 Million | ▼ -21.5 pp |
| 2017 | 82.6% | ILA43.65 Million | ILA52.88 Million | ILA50.38 Million | ILA6.72 Million | ▼ -10.1 pp |
| 2016 | 92.6% | ILA32.44 Million | ILA35.03 Million | ILA36.10 Million | ILA3.66 Million | ▼ -2.0 pp |
| 2015 | 94.6% | ILA45.04 Million | ILA47.61 Million | ILA48.18 Million | ILA3.14 Million | ▼ -6.8 pp |
| 2014 | 101.4% | ILA32.21 Million | ILA31.77 Million | ILA35.11 Million | ILA2.90 Million | ▼ -33.6 pp |
| 2013 | 135.0% | ILA15.77 Million | ILA11.68 Million | ILA18.77 Million | ILA3.00 Million | ▲ +29.8 pp |
| 2012 | 105.2% | ILA15.75 Million | ILA14.97 Million | ILA22.18 Million | ILA6.43 Million | ▲ +14.7 pp |
| 2011 | 90.5% | ILA20.40 Million | ILA22.53 Million | ILA27.16 Million | ILA6.75 Million | — |